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Abstract CD44 is a complex family of molecules, associated
with aggressive malignancies and cancer stem cells. However,
the role of CD44 variants in tumor progression and treatment
resistance is not clear. In this study, the expression of CD44
and its variants was assessed in head and neck squamous cell
carcinomas (HNSCC). Furthermore, subpopulations of cells
expressing high amounts of CD44 variants were identified and
characterized, for e.g., cell cycle phase and radioresistance.
Results revealed high and homogenous CD44 and CD44v7
expression in four cell lines and CD44v4 and CD44v6 in three
cell lines. CD44v3 was highly expressed in two cell lines,
whereas CD44v5, CD44v7/8, CD44v10, CD133, and CD24
demonstrated no or moderate expression. Moreover, a sub-
population of very high CD44v4 expression was identified,
which is independent of cell phase, demonstrating increased
proliferation and radioresistance. In cell starvation experi-
ments designed to enrich for cancer stem cells, a large popu-
lation with dramatically increased expression of CD44,
CD44v3, CD44v6, and CD44v7 was formed. Expression
was independent of cell phase, and cells demonstrated in-
creased radioresistance and migration rate. Our results dem-
onstrate that the heterogeneity of tumor cells has important
clinical implications for the treatment of HNSCC and that
some of the CD44 variants may be associated with increased
radioresistance. Highly expressed CD44 variants could make
interesting candidates for selective cancer targeting.
Keywords CD44 . CD44 isoforms . HNSCC . Cancer stem
cells . Radioresistance . Radio-immuno targeting
Introduction
Worldwide, approximately 500,000 new cases of head and
neck cancer are diagnosed each year [1, 2], and about 50 % of
these patients will eventually die of the disease [3]. About
85 % of all head and neck tumors are carcinomas. This cancer
type originates in the epithelium, the cells that form the lining
of the mouth, nose, throat, or ear or the surface layer covering
the tongue. Squamous cell carcinoma is the predominant
histological type among carcinomas [4], accounting for ap-
proximately 5 % of all malignant neoplasms in Europe and
USA. Even though the early stages of the disease are associ-
ated with a good prognosis, there is still a high failure rate for
the more advanced stages, locally as well as at distant sites [5].
This is primarily due to late disease presentation and lack of
suitable markers to detect the progression of the disease and to
predict treatment outcomes. The current treatment options for
head and neck squamous cell carcinoma (HNSCC) include
surgery, radiotherapy, and in certain cases, chemotherapy,
often in combination. However, the current treatment modal-
ities often fail in the therapy of advanced disease, as they offer
no satisfactory means to locate or treat metastases selectively
without harming adjacent tissues [6]. An effective adjuvant
systemic therapy for minimal residual disease is therefore
needed to improve the survival rate and improve quality of
life for this patient category.
Selective targeting of cancer cells based on cell surface
molecules may enable personalized diagnosis and treatment,
which promises to lower adverse effects and increase
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treatment efficacy, improving patient survival and quality of
life. Tumors are, however, highly heterogeneous, and it is
important to identify especially aggressive, chemo-, and/or
radioresistant tumor subpopulations for effective treatments
[7].
One interesting target is CD44 and its isoforms. CD44 is a
complex family of molecules, produced from one gene by
alternative splicing and posttranslational modifications. To
date, dozens of different CD44 isoforms have been discov-
ered; the most common one is the standard CD44 (CD44s), in
which exon 5 is spliced directly to exon 16, skipping the entire
variant exon sequence [8, 9]. Exons 6–15 are variable exons,
alternatively spliced in insertion site between 5 and 16, gen-
erating various isoforms of the molecule. These variable
exons are identified as v1–v10, respectively. The isoforms
mostly differ in size and conformation of the extracellular
domain, which determines what binding partner the receptor
interacts with. Accordingly, the CD44 family is involved in
cell–cell and cell–matrix interactions and signal transduction
[10]. They are not only essential to multiple biological func-
tions of normal cells but also crucial to many tumor cell
activities, as malignant cells often express unique patterns of
CD44 isoforms [11].
Several studies have found CD44 to have a role in impaired
prognosis in many malignant tumors, such as hepatic carcino-
ma, lung carcinoma, breast carcinoma, melanoma, gastric
carcinoma, and HNSCC. Moreover, overexpression of
CD44 in tumors has been shown to predict an increased
resistance to chemotherapy and radiation and an increased
risk of local recurrence [12]. Furthermore, several studies
describe CD44 to be a cancer stem cell marker for various
malignancies [13, 14]. This makes it a highly interesting
candidate for selective cancer targeting. However, antibody-
sorting assays of CD44 used in these studies do not only select
cells expressing the standard CD44s molecule, but this sorted
population may also contain any CD44 splice variants. If one
or several CD44 splice variants are found to be associated
with cancer progression or treatment resistance, the possibility
of targeting such a population will increase immensely, since
these isoforms are not as abundantly expressed in the normal
tissue as the standard CD44s molecule.
Besides CD44, a number of CDmarkers have been identified
as cancer stem cell markers in several solid tumors. The glyco-
protein CD133, also known as prominin1, is a stem cell surface
antigen in brain, colorectal, and prostate cancer [15]. Another
cell surface marker is the single-chain sialoglycoprotein CD24,
which is associated with cancer stem cell characteristics in
colorectal and pancreatic cancer, while head and neck cancer
cells and breast cancer cells with CD44+CD24−/low expression
are highly tumorigenic [16–18].
The scope of this study was to study the expression of
potential cancer stem cell markers CD133, CD24, and
CD44, with focus on CD44 exon variants in head and neck
squamous cell carcinoma, in order to find attractive molecular
targets for selective cancer targeting. The extent of variant
expression was first studied in several HNSCC cell lines, and
possible subpopulations of cells expressing high amounts of
one or several variants were then identified. The role of these
subpopulations with regards to, e.g., cell cycle phase, migra-
tion rate, proliferation, and radioresistance was then assessed.
Material and methods
Cell lines and culture conditions
Standard culture conditions
The HNSCC cell lines SCC-25 (derived from SCC of the
tongue), obtained from American Type Culture Collection,
and H314 (floor of mouth, STNMP stage II, moderately
differentiated, node positive tumor), obtained from European
Collection of Cell Cultures, were cultured in a 1:1 mixture of
Ham’s F12 and Dulbecco’s modified Eagle medium
(DMEM), supplemented with 10 % fetal calf serum, 2 mM
L-glutamine, and antibiotics (100 IU penicillin and 100 μg/ml
streptomycin). The HNSCC cell lines UT-SCC7 (metastasis/
neck, temporal skin, tumor grade 2, TNM at diagnosis
T1N0M0) and UT-SCC12 (primary, skin of nose, tumor grade
1, TNM at diagnosis T2N0M0) (kindly provided by Dr. R.
Grenman, Turku University Central Hospital, Finland) were
cultured in DMEM, 5 ml nonessential amino acids, and sup-
plements. Medium with supplements is referred to as “com-
plete medium” in this article. Cells were incubated at 37 °C in
an atmosphere containing humidified air with 5 % CO2.
Serum starvation
Cell growth under serum starvation was performed as in the
study of Okamoto et al. [19], previously shown to increase the
fraction of cancer stem-like cells. For serum starvation exper-
iments, SCC-25 and UT-SCC7 cells were grown in a cell
culture medium containing 1 % fetal bovine serum (Sigma-
Aldrich) and epidermal growth factor (EGF; Calbiochem,
Germany) and basic fibroblast growth factor (bFGF;
Calbiochem; 20 ng/ml each) for up to 5 months. Analysis
was performed by flow cytometry (see below).
Antigen expression, cell sorting, and cell cycle analysis
by flow cytometry
Antigen expression
The HNSCC cells SCC-25, UT-SCC7, UT-SCC12, and H314
were harvested by nonenzymatic cell dissociation solution
(Sigma-Aldrich, St. Louis, USA) and washed three times in
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phosphate-buffered saline (PBS) containing 0.5 % bovine
serum albumin (BSA). Then, cells were incubated for
10 min with labeled antibodies [phycoerythrin (PE)-conjugated
anti-CD133 1:100, allophycocyanin (APC)-conjugated anti-
CD44 1:1,000, and fluorescein isothiocyanate (FITC)-conju-
gated anti-CD24 1:100 (eBioscience, San Diego, USA); FITC-
conjugated mouse antihuman v4, v5, v6, v7, v7/8, and v10 (all
from AbD Serotec, Kidlington, UK); and PE-conjugated
mouse antihuman CD44v3 and CD44v4/5 (R&D Systems,
Minneapolis, USA)]. Respective immunoglobulin G (IgG)
isotype-matched controls, APC-conjugated rat IgG2b 1:1,000,
PE-conjugated mouse IgG1 1:100, and FITC-conjugated
mouse IgG1 1:100 (AbD Serotec, Kidlington, UK;
eBioscience, San Diego, USA; R&D Systems, Minneapolis,
USA), were used as negative controls.
Cells were washed three times with PBS with 0.5 % BSA
and analyzed with the BD LSRII SORP (Becton Dickinson
Biosciences, San Jose, USA) flow cytometer. Debris and
apoptotic cells were stained with propidium iodide (Sigma-
Aldrich) and excluded from analysis. The experiments were
repeated at least three times.
Cell cycle progression
To determine if the CD44 variant expression pattern was con-
sistent through the cell cycle, cell cycle studies were performed.
To first ensure that the cells progress through the cell cycle in a
synchronous manner, SCC-25, UT-SCC7, and UT-SCC12
were grown in low serum (0.5 %) condition. Depending on
the doubling time of the HNSCC cell lines, cells were
maintained in low serum media for 12–48 h. After quiescence
in G0 phase, cells were released by adding a complete culture
medium and harvested at different time points.
For analysis of CD44 and CD44 variant expression through
the different phases of the cell cycle, cells were detached with
nonenzymatic cell dissociation solution (Sigma-Aldrich,
Stockholm, Sweden), washed in PBS with 0.5 % BSA, and
fixed in ice-cold 70 % ethanol. Cells were treated with RNase
(Sigma-Aldrich) and stained for 30 min with propidium iodide
solution with 0.1%NP-40 (Sigma-Aldrich) and 10minwith the
antibodies listed earlier, followed by analysis with the BDLSRII
SORP (Becton Dickinson Biosciences, San Jose, USA) flow
cytometer. Un-synchronized cells were stained as above and
used as a control. The percentages of cells in the different cell
cycle phases (G0/G1, S, or G2/M phase) were determined using
FACSDiva (Becton Dickinson Biosciences, San Jose, USA)
and ModFit LT (Verity Software House, Tosham, ME, USA)
software. Each experiment was repeated at least three times.
Fluorescence-activated cell sorting
For the sorting experiments, UT-SCC7 cells were prepared as
described earlier in antigen expression and evaluated in a
FACSVantage SE DiVa (Becton Dickinson Biosciences, San
Jose, USA). Populations were gated, and the cell populations
expressing the marker to high extent and low extent were
separated.
Cell proliferation, radiation resistance, and migration studies
Cell proliferation and radiation resistance
Proliferation- and radiation-mediated effects in subpopula-
tions or starved cells were studied using clonogenic survival
assays on SCC-25 or UT-SCC7 cells.
For clonogenic characterizations of starved cells, untreated
and serum starved SCC-25 cells were grown for 4–16 weeks.
Clonogenic survival assays were performed in triplicates.
Here, a defined amount of cells (200 to 10,000, depending
on radiation dose) was pre-plated into 25-cm2 tissue culture
flasks with 8 ml complete medium. After 24 h, cells were
exposed to external beam radiation using a 137Cs source (Best
Theratronics Gammacell® 40 Exactor, Springfield, USA),
irradiated with 0, 2, 4, 6, and 8 Gy. After an incubation period
of approximately 10–14 days, cells were washed in PBS and
stained with crystal violet. Colonies of greater than 50 cells
per colony were counted manually. Plating efficiency (PE)
(number of colonies formed/number of colonies seeded in the
control) and the survival fraction (SF) (number of colonies
formed after treatment/number of cells seeded×PE) were
calculated. Linear quadratic curve fit (S =exp (−αD −βD2),
where D =radiation dose in Gray, and α and β are fitting
parameters) was calculated by using the GraphPad Prism 5
software (San Diego, CA, USA). Significance testing was
made using two-tailed Student’s t test and was considered
significant if P <0.05. Experiments were repeated at least
three times.
For subpopulation analysis, defined subpopulations of UT-
SCC7 cells were sorted using FACSVantage SE DiVa as
described above, and a defined amount of cells was plated in
triplicates. After 24 h, cells were exposed to 2 Gy external
beam radiation using a 137Cs source (Best Theratronics
Gammacell® 40 Exactor, Springfield, USA). After an incuba-
tion period of approximately 10–14 days, cells were washed
in PBS, stained with crystal violet, and analyzed as described
above.
Cell migration
The migratory activity of starved cells was studied using the
scratch assay, as previously reported [20], on SCC-25 cells.
Briefly, cells were grown in triplicates under normal and
starvation growth conditions in six-well plates for 4–6 weeks
(see above). Cells were washed and incubated with corre-
sponding cell medium. Then, a narrow area on the confluent
cell monolayers was scratched off with a p200 pipette tip.
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Cells were allowed to migrate for 8–12 h, images from the
same areas were obtained using the Nikon D3000 Digital
Cameramounted on an invertedmicroscope. The images were
analyzed with the ImageJ software (National Institutes of
Health, Bethesda, Maryland). Significance testing was made
using two-tailed Student’s t test and was considered signifi-
cant if P <0.05. Experiments were repeated three times.
Results
Characterizations in standard culturing conditions
General antigen expression assessed by flow cytometry
The expression pattern of all investigated antigens is summa-
rized in Table 1. Examples of the expression pattern after
analysis with flow cytometry can be seen in Fig. 1. All four
investigated HNSCC cell lines showed no or low expression
patterns for CD24. CD133 was moderately expressed in three
of four cell lines, whereas all cell lines were positive for CD44
expression. Since the staining for CD44 only gives informa-
tion about the total expression of CD44, but not for the ratios
between different splice variants and the CD44 standard form,
the expression pattern of CD44 exon isoforms was also inves-
tigated. The extent of expression varied only slightly between
the cell lines. CD44v4, CD44v6, and CD44v7 were highly
expressed in all tested HNSCC cell lines, whereas CD44v5,
CD44v8, and CD44v10 occurred to lesser extent. The
CD44v3 level in UT-SCC7 and UT-SCC12 was high, while
SCC-25 and H314 moderately expressed this marker
(Table 1).
Antigen subpopulations assessed by flow cytometry
A homogenous expression with no clear subpopulations was
seen for all assessed markers in standard culturing conditions,
except for CD44v4. This interesting CD44v4 population
consisting of highly expressing cells (CD44v4++) was found
in the investigated cell lines. These cells differed markedly
from the bulk of all HNSCC tumor cells and appeared as a
clear subpopulation (Fig. 2a). This subpopulation was about
19% inUT-SCC7 cells and 7, 9, and 10% inUT-SCC12 cells,
SCC-25 cells, and H314 cells, respectively. Furthermore, this
expression seemed to be cell cycle independent, as cell cycle
studies confirmed unchanged expression of CD44 and
CD44v4 throughout the different cell cycle phases (data not
shown).
Antigen subpopulations assessed by clonogenic assays
Next, we examined proliferation and sensitivity to radiation of
the subpopulation of highly CD44v4-expressing cells in com-
parison to cells with the lesser extent of CD44v4 in the cell
line with the largest CD44v4++ subpopulation (UT-SCC7,
Fig. 2b). Highly expressing cells were isolated from the bulk
of tumor cells and cultured separately. Immediately after
separation, clonogenic survival assays were performed on
the separated populations. The plating efficiency of
CD44v4++ cells was increased by approximately 20 % com-
pared to CD44v4+ cells. Moreover, v4++ cells were exten-
sively more resistant to radiation treatment than CD44v4+
cells. More than 70 % of CD44v4++ cells kept their colony-
forming ability after a radiation dose of 2 Gy, while less than
half (around 34 %) of CD44v4+ cells were able to grow into a
colony.
Characterizations in serum starvation conditions
Morphology and antigen expression assessed by flow
cytometry
SCC-25 and UT-SCC7 cultured under low serum conditions
underwent clear morphological changes, while cells under
normal conditions did not. Starved cells grew slowly and
formed tight cell aggregates. Flow cytometry analysis showed
that both starved and non-starved cells were positive for CD44
expression. However, the amount of highly CD44-expressing
cells had increased in the cell populations under starvation
conditions. After 4 months of starvation, an average of 59 %
Table 1 Expression pattern of CD44, CD44 exon variants, CD133, and CD24. The expression levels were measured by flow cytometry and graded on a
relative scale to isotope control (expression baseline)
Cell line Expression of the marker
CD133 CD24 CD44 v3 v4 v5 v6 v7 v7/8 v10
UT-SCC7 + − ++ ++ ++ + ++ ++ − +
UT-SCC12 + − ++ ++ ++ + ++ ++ − +
SCC-25 + − ++ + ++ − ++ ++ − +/−
H314 +/− − ++ + + − + ++ − −
– low or no expression; + moderate expression; ++ high expression; N =2–6
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for UT-SCC7 and 90 % of SCC-25 had at least doubled their
CD44 expression (Fig. 3). Even though the expression pattern
for CD44 changed, the CD44 variants v5, v7/8, and v10 did
not. However, a substantial increase of CD44, CD44v3,
CD44v6, and CD44v7 and a slight increase for CD44v4/5 were
found in both cell lines. After serum starvation of 4 months, the
CD44 expression had increased with 90 % in SCC-25 and with
59% in UT-SCC7 cells. UT-SCC7 control cells, cultured under
normal conditions, were positive for CD44v3, CD44v6, and
CD44v7, but only a minority of cells (3 % for CD44v3, 4 % for
CD44v6, and 2 % for CD44v7) did overexpress the marker. In
contrast, more than 70 % of the serum starved cells
overexpressed variant v3, and more than 80 and 50 %,
v6 and v7, respectively, after 4 months of treatment
(Fig. 3). Similar results were obtained for SCC-25 cells.
Here, the CD44v4/5 variant increased with about 15 %;
v3 expression, with 60 %; v6, with 75 %; and v7, with
about 21 % (Fig. 3).
Fig. 1 Example of FACS analysis of three markers differently expressed
in the HNSCC cell line SCC-25. a Example of a marker, CD24, which
displayed no or low expression. b Example of a marker, CD44v3, which
displayed moderate expression. c Example of a marker, CD44v6, which
displayed a high expression
Fig. 2 a Dot plot and histogram of FACS analyzed UTSCC-7 and SCC-
25 cells. All cell lines were positive for CD44v4 (purple population).
Additionally, a distinct subpopulation with CD44v4 overexpressing cells
was found (green population). b Clonogenic survival assay of FACS-
sorted UT-SCC7 cells. CD44v4-positive and CD44v4 overexpression
cells treated with a radiation dose of 2 Gy. CD44v4+ and CD44v4++
groups are normalized for plating efficiency (unirradiated controls).
Analyses of variance was made using Student’s t test and was considered
significant if P<0.05. The error bars represent standard deviation (SD),
N =3
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Furthermore, to determine if the CD44 variant expression
pattern was consistent through the cell cycle, cell cycle studies
were performed. Neither CD44 nor any of the other CD44
exon isoforms appeared to change noticeably throughout the
cell cycle (data not shown).
Radiation resistance and migration of starved cells assessed
by clonogenic and scratch assays
To examine if previously starved and, hence, CD44 positive
(Fig. 4a) cells differed in their ability to survive radiation
treatment, clonogenic survival assays were performed on
SCC-25 cells (Fig. 4b). Previously starved cells were clearly
more resistant to radiation than normal cells, statistically sig-
nificant (P <0.05) for 4, 6, and 8 Gy. Approximately 25 % of
starved cells survived a radiation dose of 4 Gy, whereas only
12 % of non-starved cells could form a colony after the same
treatment. The difference was even more pronounced at a
radiation dose of 6 and 8 Gy. Migration analysis was also
assessed for SCC-25 cells starved for 4–6 weeks. Starved cells
migrated significantly (P <0.001) faster than non-starved
cells, demonstrating a migration rate of 0.045±0.002 mm/h
compared to 0.017±0.003 mm/h for non-starved cells.
Discussion
The purpose of this study was to examine the expression of the
cancer stem cell markers CD133, CD24, CD44, and CD44
variants, in head and neck squamous cell carcinoma. The aim
Fig. 3 FACS analysis of UT-
SCC7 and SCC-25 cells. Change
of CD44, v3, v4/5, v6, and v7
marker expression under
starvation condition, normalized
to their controls. Marker
expression of non-starved cells is
set to 0 %. Error bars=SD,
N ≥2–4
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was to find suitable molecular targets for radio-
immunodiagnostics and therapy and to clarify if any of the
CD44 splice variants may be associated with radioresistance.
Furthermore, since serum-starved conditions have been
shown to increase the amount of CD44-positive cancer
stem-like cells [19], we wanted to elucidate if this increase
was also true for any of the CD44 splice variants. It is impor-
tant to emphasize that most antibody-mediated expression
analyses of CD44, such as immunohistochemistry (IHC) or
FACS analyses, will not distinguish between standard CD44s
or any of the CD44 isoforms, as they all share the same
standard region. As a majority of studies have not taken into
consideration that such CD44 analyses will detect a collection
of isoforms, it is not surprising that no consensus opinion has
been reached on the role of CD44 and its isoforms in tumor
progression and cancer stem cells. Hence, it is yet not known
if one or several CD44 isoforms can be utilized as markers for
radioresistance or even cancer stem cell markers.
Whereas some tumors such as gliomas exclusively express
CD44s, other neoplasms including gastrointestinal cancer,
bladder cancer, uterine cervical cancer, breast cancer, and
HNSCC also express CD44 variants. This may be due to a
loss of CD44 splice control mechanisms in malignant tumors.
Overexpression of several CD44 isoforms has been associated
with tumor progression, suggesting that these isoforms may
have unique signaling properties. Hence, CD44, particularly
its variants, may be used as diagnostic or prognostic markers
of at least some human malignant diseases [21], even enabling
specific targeting of aggressive, resistant, or regrowing sub-
populations. However, not much is known today about the
role of most of these variants in malignancies, cancer stem
cells, and HNSCC.
In this study, flow cytometry analysis was first used to
assess the extent of CD133, CD24, and CD44 variant expres-
sion in four HNSCC cell lines. Our results demonstrated high
and homogenous expression of CD44 and CD44v7 in four
cell lines and CD44v4 and CD44v6 in three of the cell lines.
CD44v3 was highly expressed in two cell lines, whereas
CD44v5, CD44v7/8, CD133, and CD24 demonstrated no or
low expression.
CD44 isoforms containing exon v3 have recently drawn
attention since this exon includes a growth factor-binding site
(such as HGF, bFGF, and HB-EGF), and this domain seems to
be critical to the metastasis phenotype [22, 23]. Studies sug-
gest that CD44v3-containing isoforms are overexpressed at
the mRNA level in HNSCC tissues compared to normal
controls and may be associated with HNSCC cell growth
[23]. CD44v3-containing isoforms have also been associated
with HNSCCmigration, clonal formation, cisplatin resistance,
and matrix metalloproteinase activity and have been identified
in lymph node metastasis [24, 25]. CD44v3 isoforms may,
therefore, be effective tumor markers and targets for HNSCC
therapy. It is interesting to note that in our study, CD44v3 was
highly expressed in the two SCC cell lines derived from the
Fig. 4 a FACS analysis of SCC-25 cells under normal growth condition
and after serum starvation of 4 months (1 % FBS, 20 ng/ml EGF and
bFGF) for CD44. Serum starvation increased the amount of cells highly
expressing the marker. b Clonogenic survival assay of SCC-25 cells
under normal growth condition and after serum starvation of 4 months
(1 % FBS, 20 ng/ml EGF and bFGF). Normal SCC-25 cells are more
sensitive to radiation than previously starved SCC-25 cells. Survival data
was fit to a linear quadratic curve. The error bars represent SD. N ≥9
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skin (UT-SCC7 and UT-SCC12), whereas the SCC cell lines
derived from the tongue and floor of mouth (SCC-25 and
H314, respectively) demonstrated a moderate CD44v3 ex-
pression. A similar difference could also be seen for
CD44v5 and CD44v10 expression (moderate versus no/low
expression). However, a much larger panel of cell lines, pref-
erably complemented with expression studies in patient tumor
tissue, would be needed in order to draw any conclusions on
CD44 variant expression correlated to tumor origin or tumor
progression. Furthermore, since cell lines were cultured
according to provider instructions, UT-SCC7 and UT-
SCC12 cells were cultured in a slightly different medium than
SCC-25 and H314, further complicating such comparisons.
Expression of CD44v4 has been associated with metastasis
in two studies of breast cancer cells and esophageal squamous
cell carcinoma, where it was shown to be a major E-selectin
ligand in facilitating tumor cell migration across endothelial
monolayers, mediating breast cancer cell transendothelial me-
tastasis [26]. Furthermore, expression of CD44v4/5 in esoph-
ageal squamous cell carcinoma has been linked to infiltration
and metastasis [27]. However, not much is known about the
role of CD44v4 in HNSCC. It is, therefore, exciting that such
a clear overexpression of CD44v4 was found in our assessed
cell lines, indicating that CD44v4 has potential to be used as a
novel tumor marker. An interesting subpopulation (>7 %) of
very high antigen expression was identified in all four cell
lines in our study. This subpopulation displayed increased
proliferation and radiation resistance after external beam irra-
diation with 2 Gy. One hypothesis of these results could be
that CD44v4 is associated with a more dormant phase.
However, the CD44v4 expression was shown to be indepen-
dent of cell phase, making this theory less likely. Previous
studies have demonstrated a connection between radiation and
E-selectin, suggesting that ionizing radiation induces E-
selectin protein expression in human endothelial cells and,
therefore, increasing tumor cell adhesion [28, 29]. Thus, an
alternative explanation for the CD44v4-associated radiation
resistance may be that CD44v4 functions as an E-selectin
ligand, mediating increased adhesion properties at radiation
exposure. We conclude from these results that not only CD44s
but also CD44v4 seems to be associated with radioresistance
and that CD44v4 may be an interesting tumor marker to be
further studied.
CD44v6 is currently the most established tumor antigen
among the CD44 splice variants. The large difference in expres-
sion between healthy and malignant cells makes the CD44v6
antigen an attractive target for radio-immunodiagnostics and
therapy. The anti-CD44v6 antibody U36 has been extensively
studied in patients with primary HNSCC and lymph node
metastases [30] and been evaluated with encouraging results in
clinical trials using 186Re as a therapeutic radionuclide [31].
CD44v6 is known to be expressed in many types of human
cancer, including HNSCC. It has been shown to function as a
co-receptor of the c-Met protein [32] and has been suggested to
be involved in tumor formation, tumor cell invasion, and me-
tastasis formation [30]. One distinctive CD44 isoform, so-called
pMeta-2 and containing the various exons 6 and 7, has drawn
attention since it is associated with cancer aggressiveness and
metastatic behavior [33]. It is, therefore, not surprising that we
found a high CD44v6 expression in three of our assessed cell
lines, verifying the established position of CD44v6 as a marker
for HNSCC. Even more interesting, CD44v6 and CD44v7 and,
to some extent, CD44v3 were also shown to be highly relevant
in cell starvation experiments.
In these starvation experiments, designed to increase the
population of cancer stem-like cells, we were able to enrich
the proportion of CD44-positive cells by culturing in low
serum containing cell medium with EGF and bFGF. This is
in line with previous results by Okamoto et al. [19]. The
properties of serum starved cells with regards to, e.g., cell
cycle phase, proliferation, migration, and radioresistance were
evaluated. So far, CD44 expression on cancer cells has been
shown to regulate multiple aspects of cancer cell phenotypes,
modulating tumor proliferation, migration, invasion, and an-
giogenesis. We found that serum-starved CD44-enriched cells
had an increased radioresistance and migration rate compared
to non-starved cells, indicating an important role for clinical
applications. While CD44 has been defined as a cancer stem
cell marker in many tumor entities, it remains to be explored
whether these cancer stem cells preferentially express CD44s
or any CD44 splice variants [34]. Further analysis of highly
CD44-expressing cells demonstrated that the antigen expres-
sion for CD44 variants was practically unchanged for the
analyzed variants, except for CD44v3, CD44v6, and
CD44v7 (Fig. 3), as previously mentioned. This is in line with
a study on colorectal adenocarcinoma by Bánky et al., where
high expression levels of CD44v3 and CD44v6 were found to
be characteristic to metastatically potent tumor cells, and
CD44 variant isoforms were described to act as “metastasis
genes” via tumor microenvironment-driven shifts in v3 and v6
expressions [35]. In our study, a large subpopulation of dra-
matically increased expression was formed for these isoforms.
Moreover, we noticed that the morphology of the starved cells
was altered, which renders fewer cells growing as a monolayer
and a larger proportion of cells growing three-dimensionally.
We speculate that these conformational changes might in part
be caused by the increased CD44 expression. From these
results, we conclude that the previously found CD44 increase
in “cancer stem-like cells” may also consist of several splice
variants, primarily CD44v3, CD44v6, and CD44v7, and that
these splice variants should be further assessed concerning
their connection to cancer stem cell-like properties. It is,
however, important to note that these results are based on a
limited selection of cell lines. Clearly, more studies are needed
to further validate this approach, especially by investigating
CD44 expression levels in various patient tissue biopsies.
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Even though IHC is commonly used for the analysis of patient
biopsies, it is a comparatively blunt method and might be
unable to satisfactorily distinguish between moderately and
highly CD44 variant-expressing cells within the same biopsy.
It is, therefore, likely that alternative methods such as FISH or
RT-PCR will have to be used as a complement. Another
important aspect is the molecular mechanism underlying the
radioresistance of highly CD44 variant-expressing cells,
which warrants further investigation.
In conclusion, we have identified several markers that are
highly expressed in cultured HNSCC cells, and we have also
identified splice variants associated with increased
radioresistance and migration rate. Highly expressed variants
of CD44 may also be a more specific marker than standard
CD44s, which is present to high extent also in normal tissue.
Our results demonstrate that the heterogeneity of tumor cells
has important clinical implications for the treatment of
HNSCC. In the future, CD44 variants may be used as prog-
nostic markers or therapeutic targets. By characterizing these
novel molecular tumor markers, we hope to advance our
understanding of the molecular and biological mechanisms
involved in carcinogenesis and tumor progression and to find
unique CD44 isoform and expression fingerprints of the vary-
ing cell types present in tumors. This could enable the specific
targeting of aggressive, resistant, and regrowing subpopula-
tions and provide more sensitive and specific methods for
identifying and treating head and neck cancer in the future,
which, in turn, is likely to manifest as increased treatment
success rates and posttreatment lifetime expectancies of
HNSCC patients.
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